RxDoctor Payments Data

Michele Gunning

Psychiatry · Peterborough, NHNPI 1144421132

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 56.0% of the total. Among psychiatry clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,882in general payments, 2019–2025

Across 337 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Neurocrine Biosciences, Inc.$497
  • Vanda Pharmaceuticals Inc.$461
  • Johnson & Johnson$447
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$360
  • Lundbeck LLC$347
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$7,71498%
  • Education$1672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,882 in reported general payments places this provider in the 90th percentile of 166 psychiatry providers in New Hampshire.

See all psychiatry providers in New Hampshire

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl98$168,522
CaplytaLumateperone Tosylate25$44,413
BelsomraSuvorexant53$25,811
EmsamSelegiline12$25,125
Lisdexamfetamine Dimesylate88$24,641
Lurasidone Hcl32$20,213
TrintellixVortioxetine Hydrobromide25$18,033
Duloxetine Hcl140$18,028
Aripiprazole87$15,480
Lamotrigine ErLamotrigine55$13,332
Topiramate ErTopiramate17$12,972
AdderallDextroamphetamine/Amphetamine13$11,616
Adderall XrDextroamphetamine/Amphetamine31$9,728
Quetiapine Fumarate ErQuetiapine Fumarate73$9,470
Quetiapine Fumarate298$8,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$4,414$168,52298 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$360$44,41325 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall, Vyvanse$39$34,83852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 166 psychiatry providers in New Hampshire.

Other psychiatry in Peterborough

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →